Epigenome wide association study of SNP–CpG interactions on changes in triglyceride levels after pharmaceutical intervention: a GAW20 analysis

Table 4 Summary of 176^a interaction pairs

Gene	Chr	# of significant interactions^b(total)	Smallest interaction p value	SNP pvalue^c	CpG pvalue^c	SNP location (bp)	Interaction (rs#:cg#)
APOA1	11	11 (57)	0.00678	0.591	0.310	116,759,824	rs12294191:cg07700644
APOB	2	9 (31)	0.00316	0.414	0.518	21,205,457	rs10172650:cg26118553
BUD13	11	31 (126)	0.00103	0.787	0.837	116,652,301	rs4417316:cg14371153
CLIP2	7	7 (74)	0.00318	0.214	0.983	73,671,288	rs3735504:cg08495433
FADS1	11	4 (52)	0.0193	0.0921	0.0831	61,549,458	rs174534:cg07689907
FADS2	11	10 (53)	0.00228	0.217	0.432	61,549,458	rs174534:cg11880646
FADS3	11	9 (45)	0.0183	0.861	0.690	61,698,488	rs7928792:cg03046346
GALNT2	1	69 (288)	0.000142	0.780	0.998	230,337,887	rs6677241:cg03961853
MLXIPL	7	16 (98)	0.00220	0.613	0.298	73,041,886	rs6460045:cg03842980
OTOR	20	10 (60)	0.00934	0.196	0.581	16,702,501	rs761228:cg07364906

^aAs a result of overlap of gene regions for FADS1 and FADS2, 3 significant interactions are counted twice
^bWith a significance level of 0.05
^cFrom models with only the main effect term for CpG or SNP. Refer to methods

ISSN: 1753-6561